Mantle cell lymphoma: A clinically heterogeneous disease in need of tailored approaches

Cancer Control

Volumn 19, Issue 3, 2012, Pages 227-235

  Shah, Bijal D ^a   Martin, Peter ^b   Sotomayor, Eduardo M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CARMUSTINE; CHLORMETHINE; CLADRIBINE; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 11; LENALIDOMIDE; METHOTREXATE; PCI 37625; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMSIROLIMUS; TENIPOSIDE; TRANSCRIPTION FACTOR SOX11; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT;

AGE DISTRIBUTION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CAUSAL ATTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ELDERLY CARE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; INFECTION; INFUSION RELATED REACTION; LEUKOCYTE COUNT; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84864517637     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900307     Document Type: Article

References (100)

1. Klapper W. Histopathology of mantle cell lymphoma. Semin Hematol. 2011;48(3):148-154.
2. Kraus TS, Sillings CN, Saxe DF, et al. The role of CD11c expression in the diagnosis of mantle cell lymphoma. Am J Clin Pathol. 2010;134(2): 271-277.
3. Pott C. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. Semin Hematol. 2011;48(3):172-184.
4. Hankin RC, Hunter SV. Mantle cell lymphoma. Arch Pathol Lab Med. 1999;123(12):1182-1188.
5. Li JY, Gaillard F, Moreau A, et al. Detection of translocation t(11;14) (q13;q32) in mantle cell lymphoma by fl uorescence in situ hybridization. Am J Pathol. 1999;154(5):1449-1452.
6. Belaud-Rotureau M-A, Parrens M, Dubus P, et al. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol. 2002;15(5):517-525.
7. Dreyling M, Hiddemann W; the European MCL Network Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009:542-551.
8. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008; 113(4):791-798.
9. Chandran R, Gardiner SK, Simon M, et al. Survival trends in mantle cell lymphoma in the United States over sixteen years 1992-2007. Leuk Lymphoma. 2012;1-18. 2012 Feb13. Epub ahead of print.
10. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1): 265-276.
11. Schöllkopf C, Melbye M, Munksgaard L, et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood. 2008;111(12):5524-5529.
12. Wang S, Slager S, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109(8):3479-3488.
13. Skibola CF, Bracci PM, Nieters A, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010;171(3): 267-276.
14. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118(11):3088-3095.
15. Thelander EF, Rosenquist R. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leuk Lymphoma. 2008;49(6):1042-1049.
16. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209-1213.
17. Martin P, Leonard J. Is there a role for "watch and wait" in patients with mantle cell lymphoma? Semin Hematol. 2011;48(3):189-193.
18. Racke F, Simpson S, Christian B, et al. Evidence of long latency periods prior to development of mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2010;116(21):323.
19. Aqel N, Barker F, Patel K, et al. In-situ mantle cell lymphoma: a report of two cases. Histopathology. 2007;52(2):256-260.
20. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental fi nding with indolent clinical behavior. Haematologica. 2012;97(2):270-278.
21. Christian B, Zhao W, Hamadani M, et al. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol. 2010;28(31):e629-e632.
22. Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma. 2008;49(9):1693-1701.
23. Klapper W, Hoster E, Determann O, et al; the European MCL Network. Ki-67 as a prognostic marker in mantle cell lymphoma: consensus guidelines of the pathology panel of the European MCL Network. J Hematop. 2009;2(2):103-111.
24. Schaffel R, Hedvat C, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21(1):133-139.
25. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profi ling defi nes indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408-1418.
26. Gustavsson E, Sernbo S, Andersson E, et al. SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Molecular Cancer. 2010;9:187.
27. Shah BD, Villagra A, Merino O, et al. HDAC profi ling in mantle cell lymphoma unveils HDAC11 and HDAC10 as potential molecular targets. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2506.
28. Sahakian E, Shah BD, Powers J, et al. The opposing role of histone deacetylase 10 (HDAC10) and HDAC11 in proliferation/survival of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2011;118(21):1363.
29. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2008;27(4):511-518.
30. Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma. 2011;52(10):1929-1935.
31. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. Blood. 2008;111(2):558-565.
32. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive fi rst-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530-1533.
33. Hoster E. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin Hematol. 2011;48(3):185-188.
34. Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18Ffl uoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Molec Imaging. 2010;37:1633-1642.
35. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27(16):2739-2741.
36. Thieblemont C, Houlgatte R, Felman P, et al. Indolent mantle cell lymphoma (MCL): a retrospective detailed clinical and morphological analysis of 21 patients, with histological, cytological, cytogenetic, interphase genetic, immunoglobulin gene, and gene expression profi ling analysis. Blood (ASH Annual Meeting Abstracts). 2008;112(11):1780.
37. Nodit L, Bahler DW, Jacobs SA, et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol. 2003;34(10):1030-1034.
38. Nabhan C, Smith SM, Kahl BS. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. Leuk Lymphoma. 2012;53(5):770-778.
39. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23(4):705-711.
40. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-324.
41. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927-1932.
42. Seggewiss R, Ho AD, Kraemer A. Remarkable response to rituximab in a patient with atypical CD20++ mantle cell lymphoma of the bone marrow leading to severe pancytopenia. Ann Hematol. 2004;83(5):316-318.
43. Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP, et al. The splenic form of mantle cell lymphoma. Eur J Haematol. 2002;68(1):12-21.
44. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma. 2004;45(10):2007-2015.
45. Solenthaler M, Matutes E, Brito-Babapulle V, et al. p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica. 2002;87(11):1141-1150.
46. Leitch H, Gascoyne R, Chhanabhai M, et al. Limited-stage mantlecell lymphoma. Ann Oncol. 2003;14(10):1555-1561.
47. Zelenetz A, Abramson JS, Advani JH, et al. NCCN Clinical Practice Guidelines in Oncology, Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
48. Teodorovic I, Pittaluga S, Kluin-Nelemans J, et al. Effi cacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1995;13(11):2819-2826.
49. Fisher RI, Dahlberg S, Nathwani B, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories). A Southwest Oncology Group study. Blood. 1995;85(4):1075-1082.
50. Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006;107(5):1014-1022.
51. Borgerding A, Hasenkamp J, Glass B, et al. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol. 2010;89(3):283-289.
52. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone signifi cantly improves response and time to treatment failure, but not longterm outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-1992.
53. Lefrère F, Delmer A, Levy V, et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica. 2004;89(10):1275-1276.
54. Pott C, Hoster E, Beldjord K, et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network. Blood (ASH Annual Meeting Abstracts). 2010;116(21):965.
55. Romaguera JE. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-7023.
56. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200-208.
57. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in fi rst remission signifi cantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677-2684.
58. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120(5):793-800.
59. Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol. 2003;71(2):73-80.
60. Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007;86(2):101-105.
61. Geisler CH, Kolstad A, Laurell A, et al. Long-term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687-2693.
62. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemother apy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.
63. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119(9):2093-2099.
64. Ahmadi T, McQuade J, Porter D, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant. 2011 Nov 14. Epub ahead of print.
65. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as fi rst-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: fi nal results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts). 2009;114(22):405.
66. Inwards DJ, Fishkin PAS, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113(1):108-116.
67. Spurgeon SE, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2011;52(8):1488-1494.
68. Kenkre VP, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: longterm follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011;52(9):1675-1680.
69. Kluin-Nelemans JC., Hoster E, Walewski J, et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the fi rst randomized trial for elderly patients with mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118(21):439.
70. Le Gouill S, Mohty M, Guillaume T, et al. Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Semin Hematol. 2011;48(3):227-239.
71. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344-349.
72. Wang L, Fayad L, Hagemeister FB, et al. A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22):2719.
73. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84(9):553-559.
74. Belch A, Kouroukis C, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND 150. Ann Oncol. 2007;18(1):116-121.
75. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-4874.
76. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23(4):676-684.
77. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory b-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(4):667-675.
78. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117(10):2807-2812.
79. Kouroukis CT, Fernandez LAV, Crump M, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011;52(3):394-399.
80. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690-697.
81. Ribrag V, Gisselbrecht C, Haioun C, et al. Effi cacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009;115(19):4540-4546.
82. Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011;155(2):190-197.
83. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011;96(7):1008-1014.
84. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hema tologic malignancies. Leuk Lymphoma. 2009;50(12):1916-1930.
85. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822-3829.
86. Zhang X, Chen X, Lin J, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2011 Oct 17. Epub ahead of print.
87. Cheng F, Wang H, Woan K, et al. Targeting histone deacetylase 6 (HDAC6) as a novel approach to overcome T-cell anergy. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1483.
88. Cheng F, Wang Z, Wang H, et al. Epigenetic modulation of STAT3 by histone deacetylase 6 (HDAC6) regulates IL-10 gene expression and immune tolerance mediated by antigen-presenting cells (APCs). Blood (ASH Annual Meeting Abstracts). 2011;118(21):519.
89. Villagra A, Cheng F, Wang H-W, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10(1):92-100.
90. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61(13):5137-5144.
91. Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198-1203.
92. Holkova B, Perkins EB, Sokol L, et al. A Phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118(21):779.
93. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previouslytreated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 2011;118(21):442.
94. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1777.
95. Hoellenriegel J, Meadows S, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603-3612.
96. Chang BY, Francesco M, Magadala P, et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor, PCI-32765, in mantle cell lymphoma patients. Blood (ASH Annual Meeting Abstracts). 2011;118(21):954.
97. Gupta M, Wahner Hendrickson AE, Yun SS, et al. Dual mTORC1/ mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012;119(2):476-487.
98. Tchakarska G, Le Lan-Leguen A, Roth L, et al. The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies. Haematologica. 2009;94(12):1781-1782.
99. Leonard JP, LaCasce A, Smith MR, et al. Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2008;112(11):264.
100. Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 2008;68(14):5519-5523.